Alk-Abello A/S, of Horsholm, Denmark, released further analysis of data from its landmark five-year Grazax asthma prevention (GAP) trial in children. The analysis, which appears online in The Journal of Allergy and Clinical Immunology, shows that the benefits of Grazax in prevention of asthma symptoms were even more pronounced when treatment was initiated at an earlier age.